• 1
    Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 701713.
  • 2
    Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 10441051.
  • 3
    Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20: 137140.
  • 4
    Christensen E, Neuberger J, Crowe JP, Altman DG, Popper H, Portmann B, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985; 89: 10841091.
  • 5
    Locke IIIGR, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. HEPATOLOGY 1996; 23: 5256.
  • 6
    Corpechot C, Carrat F, Bonnand A-M, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. HEPATOLOGY 2000; 32: 1196-1199.
  • 7
    Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-658.
  • 8
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-890.
  • 9
    Carithers RL. Primary biliary cirrhosis: specific treatment. Clin Liver Dis 2003; 7: 923-939.
  • 10
    Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past - issues for the future. J Hepatol 2000; 32: 689-702.
  • 11
    Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992; 103: 617-621.
  • 12
    Podevin P, Calmus Y, Bonnefils MT, Veyrunes C, Chereau C, Poupon R. Effect of cholestasis and bile acids on interferon-induced 2′,5′-adenylate synthetase and NK cell activities. Gastroenterology 1995; 108: 1192-1198.
  • 13
    Podevin P, Rosmorduc O, Conti F, Calmus Y, Meier PJ, Poupon R. Bile acids modulate the interferon signalling pathway. HEPATOLOGY 1999; 29: 1840-1847.
  • 14
    Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. HEPATOLOGY 2004; 39: 915923.
  • 15
    Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JCE, et al. Low-dose of methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117: 400407.
  • 16
    Bach N, Bodian C, Bodenheimer HC, Croen E, Berk PD, Thung SN, et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 187193.
    Direct Link:
  • 17
    Combes B, Emerson SS, Flye NL. The primary biliary cirrhosis (PBC) ursodiol (UDCA) plus methotrexate (MTX) or its placebo study (PUMPS): a multicenter randomized trial [abstract]. HEPATOLOGY 2003; 38 (Suppl 1): 210.